Overcoming Barriers to Diabetes Technology in Youth with Type 1 Diabetes and Public Insurance: Cases and Call to Action

Advancements in diabetes technology such as continuous glucose monitoring (CGM), insulin pumps, and automated insulin delivery provide opportunities to improve glycemic control for youth with type 1 diabetes (T1D). However, diabetes technology use is lower in youth on public insurance, and this technology use gap is widening in the US. There is a significant need to develop effective interventions and policies to promote equitable care. The dual purpose of this case series is as follows: (1) describe success stories of the CGM Time in Range Program (CGM TIPs), which removed barriers for initiating CGM and provided asynchronous remote glucose monitoring for youth on public insurance, and (2) advocate for improving CGM coverage by public insurance. We describe a series of six youths with T1D and public insurance who obtained and sustained use of CGM with assistance from the program. Three youths had improved engagement with the care team while on CGM and the remote monitoring protocol, and three youths were able to leverage sustained CGM wear to obtain insurance coverage for automated insulin delivery systems. CGM TIPs helped these youths achieve lower hemoglobin A1c and improved time in range (TIR). Despite the successes, expansion of CGM TIPs is limited by stringent barriers for CGM approval and difficult postapproval patient workflows to receive shipments. These cases highlight the potential for combining diabetes technology and asynchronous remote monitoring to support continued use and provide education to improve glycemic control for youth with T1D on public insurance and the need to reduce barriers for obtaining CGM coverage by public insurance.

[1]  R. Beck,et al.  HbA1c Levels in Type 1 Diabetes from Early Childhood to Older Adults: A Deeper Dive into the influence of technology and socio-economic status on HbA1c in the T1D Exchange Clinic Registry Findings. , 2020, Diabetes technology & therapeutics.

[2]  T. Hansen,et al.  Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: a longitudinal follow‐up study , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[3]  Korey K Hood,et al.  Association Between Adherence and Glycemic Control in Pediatric Type 1 Diabetes: A Meta-analysis , 2009, Pediatrics.

[4]  7. Diabetes Technology: Standards of Medical Care in Diabetes-2021. , 2020, Diabetes care.

[5]  M. Chin,et al.  Social Determinants of Health and Diabetes: A Scientific Review , 2020, Diabetes care.

[6]  R. Wachter,et al.  Focusing on Digital Health Equity. , 2021, JAMA.

[7]  D. Kruger,et al.  Current Eligibility Requirements for CGM Coverage Are Harmful, Costly, and Unjustified , 2020, Diabetes technology & therapeutics.

[8]  B. Buckingham,et al.  Closed loop control in adolescents and children during winter sports: Use of the Tandem Control‐IQ AP system , 2019, Pediatric diabetes.

[9]  Gregory P. Forlenza,et al.  Six months of hybrid closed loop in the real‐world: An evaluation of children and young adults using the 670G system , 2019, Pediatric diabetes.

[10]  R. Rikard,et al.  Examining health literacy disparities in the United States: a third look at the National Assessment of Adult Literacy (NAAL) , 2016, BMC Public Health.

[11]  W. Maier,et al.  A Decade of Disparities in Diabetes Technology Use and HbA1c in Pediatric Type 1 Diabetes: A Transatlantic Comparison , 2020, Diabetes care.

[12]  Korey K Hood,et al.  ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies , 2018, Pediatric diabetes.

[13]  Cde,et al.  Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial. , 2020, JAMA.

[14]  C. de Beaufort,et al.  Insulin pump therapy in children with type 1 diabetes: analysis of data from the SWEET registry , 2016, Pediatric diabetes.

[15]  M. Desai,et al.  Improving Clinical Outcomes in Newly Diagnosed Pediatric Type 1 Diabetes: Teamwork, Targets, Technology, and Tight Control—The 4T Study , 2020, Frontiers in Endocrinology.

[16]  O. Kordonouri,et al.  Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes , 2017, JAMA.

[17]  R. Beck,et al.  Race, socioeconomic status, and treatment center are associated with insulin pump therapy in youth in the first year following diagnosis of type 1 diabetes. , 2013, Diabetes technology & therapeutics.

[18]  E. Bass,et al.  Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus , 2012, Annals of Internal Medicine.

[19]  T. Danne,et al.  Reduction in Diabetic Ketoacidosis and Severe Hypoglycemia in Pediatric Type 1 Diabetes During the First Year of Continuous Glucose Monitoring: A Multicenter Analysis of 3,553 Subjects From the DPV Registry , 2020, Diabetes Care.

[20]  GrahamClaudia Continuous Glucose Monitoring and Global Reimbursement: An Update. , 2017 .

[21]  B. Perkins,et al.  Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. , 2017, The lancet. Diabetes & endocrinology.

[22]  O. Cinek,et al.  Use of continuous glucose monitoring and its association with type 1 diabetes control in children over the first 3 years of reimbursement approval: Population data from the ČENDA registry , 2021, Pediatric diabetes.

[23]  F. Huang,et al.  Artificial Pancreas as an Effective and Safe Alternative in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis , 2018, Diabetes Therapy.

[24]  David M Maahs,et al.  State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. , 2019, Diabetes technology & therapeutics.

[25]  C. Graham Continuous Glucose Monitoring and Global Reimbursement: An Update. , 2017, Diabetes technology & therapeutics.

[26]  D. Maahs,et al.  Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes , 2021, Diabetes Care.

[27]  R. Hovorka,et al.  Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis , 2018, British Medical Journal.

[28]  D. Maahs,et al.  Uninterrupted continuous glucose monitoring access is associated with a decrease in HbA1c in youth with type 1 diabetes and public insurance , 2020, Pediatric diabetes.

[29]  A. Brorsson,et al.  Does treatment with an insulin pump improve glycaemic control in children and adolescents with type 1 diabetes? A retrospective case–control study , 2015, Pediatric diabetes.

[30]  Carolyn B. Yucha,et al.  Continuous Glucose Monitors , 2014, Journal of diabetes science and technology.